Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis
about
Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesHIV Drug Resistance: Problems and PerspectivesRelationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureAntiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infectionMinor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failureEmergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmissionVirologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South AfricaLow prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010Standing genetic variation and the evolution of drug resistance in HIVLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensConsensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cellsAdherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsThe prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patientsHighly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanFirst line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyPrevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failurePrevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, ChinaCharacteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, ChinaContribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapyIntegrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteinsLongitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage TherapyHIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, ChinaA Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep PyrosequencingHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactAn Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 QuasispeciesChallenges and opportunities in estimating viral genetic diversity from next-generation sequencing dataRoutine use of microbial whole genome sequencing in diagnostic and public health microbiologyHIV-1 drug resistance and resistance testing.PCR-induced transitions are the major source of error in cleaned ultra-deep pyrosequencing dataPosition-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropismIn vivo mutation rates and the landscape of fitness costs of HIV-1.Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencingHIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase InhibitorsPrevalence and virologic consequences of transmitted HIV-1 drug resistance in UgandaEarly HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting.
P2860
Q26851997-9D48774D-9528-4702-BDC9-7AE549A01B77Q26864534-0B976C7F-6749-4D95-A761-9D00F6A4FC25Q27003431-96E79B43-6894-4159-A977-12622B838E55Q27312940-00827A6D-D840-4D44-B774-C3C80FE2A55FQ28478459-955F9ABF-FBEC-4C5F-AA79-AA4E1B1CED02Q28478779-DDC3BC0C-59B7-4D2E-A59A-9004E02568A2Q28481233-AE0E5380-B996-4F7D-B887-24D085F2FA9DQ28481468-C735B783-E67D-461C-9326-01CB2AB8242AQ28481603-3D8E878D-8AF8-487B-9F73-AE5F17B3A081Q28484153-4B5832EF-8F6B-4000-A027-EC590CA90F6CQ28485321-13E9B605-499C-488F-B98A-FA0BEDAC486BQ28487823-87B49936-C052-46CE-B8CB-DA88668132EDQ28534423-F0ED9A07-F473-46DD-BF17-FF6FC9725CC4Q28535003-2C33ECAF-F466-45A1-9B00-0F88C8ED4833Q28535577-775CCE06-A69D-49FF-BC59-D590E67499B8Q28537608-C33ECF78-4C41-4205-B00A-746BD36C2E24Q28538326-AC6CC96C-094C-4B68-99D2-81E0DEC88DFEQ28539186-2B582352-9703-4063-AA3F-791EB5B304BDQ28539368-3F84BBE1-AA97-46BC-88F7-003CB18C9EF8Q28539927-8AEBB1B9-7A89-4FE5-866C-B814DC7F929CQ28541754-CF535D93-A4E6-40AE-A5D5-817DE1D9B9CBQ28543396-97D46D1A-6601-43F7-890D-567578D9633EQ28547874-075E3CF2-1EA7-4DBC-ACF4-D10B9FC09782Q28550283-FDEE39D8-484C-46FE-B114-118C5977B1F1Q28552356-98EF7D53-B7DB-4AA7-8939-A4A60A43357EQ28552455-10891E0A-FEC6-4897-AD37-9F83662803D0Q28554999-CA60D582-AA0F-420D-8352-B8B3863212A0Q28727944-AC2D07E8-F9A0-47D9-9702-7D14036D58CDQ28728617-D8CAEB26-1D96-4119-8A86-1E51F240CFA9Q30245693-4849B2BF-D839-4832-AA90-0419B68D3FA8Q30657886-46059955-C709-4FD4-8D9A-5232DBBB5365Q31026698-7A23C529-BDED-45FC-A73A-6850DC8884EDQ33589204-A74D2B49-3D35-48E4-BCD8-C404104ED2FFQ33622927-BBF179A3-87ED-46B4-9808-3AB13A0D8DB7Q33745946-921087B1-FF8F-4877-8503-8B6EADEF868AQ33899918-4BE5F8AB-43B4-4CE7-90DC-C5087AC18FABQ33900459-43CF4512-BCF4-445D-8F9E-7F7A8398E917Q33939069-82D40E28-8328-4883-8B85-E5F90D889234Q34116836-7969B917-848C-49B0-A33E-E4383F65C563Q34226062-0B8CA54B-F5CD-46C1-BE6C-F8BC5189FA53
P2860
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Low-frequency HIV-1 drug resis ...... tic review and pooled analysis
@ast
Low-frequency HIV-1 drug resis ...... tic review and pooled analysis
@en
type
label
Low-frequency HIV-1 drug resis ...... tic review and pooled analysis
@ast
Low-frequency HIV-1 drug resis ...... tic review and pooled analysis
@en
prefLabel
Low-frequency HIV-1 drug resis ...... tic review and pooled analysis
@ast
Low-frequency HIV-1 drug resis ...... tic review and pooled analysis
@en
P2093
P2860
P50
P356
P1476
Low-frequency HIV-1 drug resis ...... tic review and pooled analysis
@en
P2093
Anna Maria Geretti
Bernard Masquelier
Daniel R Kuritzkes
Evguenia S Svarovskaia
Heather J Ribaudo
Jeffrey A Johnson
Jonathan Z Li
Karin J Metzner
Kathy Huppler Hullsiek
Martin R Jakobsen
P2860
P304
P356
10.1001/JAMA.2011.375
P407
P577
2011-04-01T00:00:00Z